disclosures paid consultant, medqia llc paid consultant, agios pharmaceuticals, inc. consultant,...
TRANSCRIPT
![Page 1: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/1.jpg)
![Page 2: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/2.jpg)
Disclosures
Paid Consultant, MedQIA LLC
Paid Consultant, Agios Pharmaceuticals, Inc.
Consultant, Genentech
Consultant, Siemens Medical Systems
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 3: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/3.jpg)
• Apparent diffusion coefficient (ADC) measured clinically reflects extracellular water• ADC is dependent on tumor cell density
(Ellingson, 2010; Sugahara, 1999; Lyng, 2000; Chenevert, 2000; Gaurain, 2001; Nonomura, 2001; Guo, 2002; Chen, 2005; Hayashida, 2006; Manenti, 2008;
Kinoshita, 2008
Cell Density (hypercellular) = ADC Cell Density (hypocellular) = ADC
Diffusion MR Characteristics of theCentral Nervous System
Viable Tumor (Dark)
Necrotic Core
Edema
ADC Map
From: Ellingson, J Magn Reson Imaging, 2010
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 4: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/4.jpg)
The Functional Diffusion Map (fDM)(Moffat, 2005; 2006; Hamstra, 2005; 2008; Ellingson, 2010)
From: Ellingson, JMRI, 2010
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 5: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/5.jpg)
Graded fDMs Allow Visualization and Quantification of Growing Tumor
+ Hypercellular+ Hypocellular
Biological CalibrationFrom: Ellingson, JMRI, 2010
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 6: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/6.jpg)
Graded fDMs Allow Better Visualization of Growing Tumor
+ Hypercellular+ Hypocellular
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 7: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/7.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 8: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/8.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 9: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/9.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Apparent diffusion coefficient (ADC) measured clinically reflects extracellular water
Large changes in ADC after anti-angiogenic therapy reflect (largely) reduction in edema
Subtle decreases in ADC after anti-angiogenic treatment are likely to contain solid / infiltrating tumor
![Page 10: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/10.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 11: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/11.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 12: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/12.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 13: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/13.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Hypotheses:
1. Traditional fDMs (single threshold) edema changes + tumor growth greater risk of failure
![Page 14: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/14.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Hypotheses:
1. Traditional fDMs (single threshold) edema changes + tumor growth greater risk of failure
2. Graded fDMs tumor growth greater risk of failure
![Page 15: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/15.jpg)
What about anti-angiogenic therapy?
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Hypotheses:
1. Traditional fDMs (single threshold) edema changes + tumor growth greater risk of failure
2. Graded fDMs tumor growth greater risk of failure
3. Graded fDMs + pre-treatment ADC + T1+C active tumor burden GREATEST RISK (BEST PREDICTOR)
Pope, Radiology, 2009; Pope, AJNR, 2011
![Page 16: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/16.jpg)
Methods
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Patients
N = 77 patients- Pathology confirmed GBM with recurrence confirmed via histology or clinical features- Regularly treated every 2 weeks per cycle with becacizumab (5-10 mg/kg)- Baseline & minimum of one follow-up with high-quality diffusion MRI
MRI
Clinical MR sequences on 1.5TT2w, FLAIR, T1w, T1+C3-5mm slice thickness
Diffusion MRI w/ twice refocused spin echo preparationADC calculated from b=0 and b=1000 s/mm2
![Page 17: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/17.jpg)
Methods
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Image Registration
All images registered to Baseline T1 weighted imagesMutual information + 12 dof transformation
Graded fDM Calculation
- Voxel-wise subtraction- Each voxel classified according to relative difference from previous calibration studies
From: Ellingson, JMRI, 2010
![Page 18: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/18.jpg)
Methods
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Traditional fDM ΔADC beyond 0.4 um2/ms
![Page 19: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/19.jpg)
Methods
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Traditional fDM ΔADC beyond 0.4 um2/ms
Graded fDM ΔADC between 0.25 and 0.4 um2/ms (7.5% probability of occurring randomly)
![Page 20: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/20.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 21: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/21.jpg)
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
From: Ellingson, Neuro Onc, 2011
ResultsConventional response does not predict survival
![Page 22: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/22.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Conventional response does not predict survival
![Page 23: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/23.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDM regions are localized to post-treatment contrast enhancement
![Page 24: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/24.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Traditional and graded fDMs both predict survival
![Page 25: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/25.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
T1+C is better than FLAIR
![Page 26: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/26.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs are better than traditional fDMs
![Page 27: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/27.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs in T1+C
![Page 28: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/28.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
ADC distribution for graded fDMs is different than traditional fDMs and contrast-enhancing regions
Chi-squared goodness of fit, P < 0.05Between CE and graded fDMsFor 46 of 77 patients
![Page 29: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/29.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
ADC distribution for graded fDMs is different than traditional fDMs and contrast-enhancing regions
Chi-squared goodness of fit, P < 0.05Between CE and graded fDMsFor 46 of 77 patients
![Page 30: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/30.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
ADC distribution for graded fDMs is different than traditional fDMs and contrast-enhancing regions
Chi-squared goodness of fit, P < 0.05Between T1+C and graded fDMsFor 46 of 77 patients
Graded fDMs FILTER
![Page 31: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/31.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs + Pre-Tx ADC Characteristics
![Page 32: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/32.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs + Pre-Tx ADC Characteristics in T1+C BEST PREDICTOR
![Page 33: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/33.jpg)
Results
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs + Pre-Tx ADC Characteristics in T1+C BEST PREDICTOR
![Page 34: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/34.jpg)
Summary
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs + Pre-Tx ADC Characteristics in T1+C BEST PREDICTOR
![Page 35: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/35.jpg)
Summary
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Graded fDMs + Pre-Tx ADC Characteristics in T1+C BEST PREDICTOR
![Page 36: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/36.jpg)
Conclusions
• Both traditional and graded fDMs in FLAIR and T1+C were predictive of OS
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 37: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/37.jpg)
Conclusions
• Both traditional and graded fDMs in FLAIR and T1+C were predictive of OS
• Subtle changes in ADC after anti-angiogenic therapy w/in T1+C may reflect active tumor burden
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 38: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/38.jpg)
Conclusions
• Both traditional and graded fDMs in FLAIR and T1+C were predictive of OS
• Subtle changes in ADC after anti-angiogenic therapy w/in T1+C may reflect active tumor burden
Graded fDMs + Pre-Tx ADC Characteristics in T1+C BEST PREDICTOR
Median Survival Advantage of 7 months
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
![Page 39: Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,](https://reader038.vdocuments.net/reader038/viewer/2022110101/56649eeb5503460f94bfcb44/html5/thumbnails/39.jpg)
Radiology• Whitney Pope, M.D., Ph.D.• Dieter Enzmann, M.D.• Jonathan Goldin, M.D.• MedQIA
Neurology/Neuro-Oncology• Timothy Cloughesy, M.D.• Albert Lai, M.D., Ph.D.• Phioanh (Leia) Nghiemphu, M.D.
Thank You!
B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA ISMRM, Montreal, 2011
Neurosurgery• Linda Liau, M.D.• Bob Shafa, M.D.• Antonio DeSalles, M.D.
Pathology• Paul Mischel, M.D.• Bill Yong, M.D.
David Geffen School of Medicine• Taryar Zaw, B.S.• Korosh Neini, M.D.• Bobby Harris, B.S.• Carissa White, B.S.
Medical College of Wisconsin• Kathleen Schmainda, Ph.D.• Peter LaViolette, B.S.